This review summarizes the current evidences regarding the use of CYC totreat SSc, its efficacy and safety profile, and currently available or tested alternative drugs for lung andskin involvement in SSc.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Fibrosis, inflammation, and vasculopathy are the main determinants of systemic sclerosis (SSc) pathogenesis.Cyclophosphamide (CYC), an alkylating agent, has been used to treat skin fibrosis and interstitiallung diseases in SSc for many years and still represents a mainstay in hematopoietic stem celltransplantation.
📊
Key Findings & Data:Despite significant effect in reducing lung functional impairment and skin tightness,CYC has a significant safety burden, including infection risk and bone marrow and bladder toxicity.Moreover, it can affect fertility and also cause a predisposition for cancer development in the future,particularly in the bladder.
💡
Conclusion & Impact:This review summarizes the current evidences regarding the use of CYC totreat SSc, its efficacy and safety profile, and currently available or tested alternative drugs for lung andskin involvement in SSc.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Fibrosis, inflammation, and vasculopathy are the main determinants of systemic sclerosis (SSc) pathogenesis.Cyclophosphamide (CYC), an alkylating agent, has been used to treat skin fibrosis and interstitiallung diseases in SSc for many years and still represents a mainstay in hematopoietic stem celltransplantation. Despite significant effect in reducing lung functional impairment and skin tightness,CYC has a significant safety burden, including infection risk and bone marrow and bladder toxicity.Moreover, it can affect fertility and also cause a predisposition for cancer development in the future,particularly in the bladder. This review summarizes the current evidences regarding the use of CYC totreat SSc, its efficacy and safety profile, and currently available or tested alternative drugs for lung andskin involvement in SSc.
🔖
Cite This Article
BRUNİ, C., FURST, D. E. (2022). The burning question: To use or not to use cyclophosphamide in systemic sclerosis. European Journal of Rheumatology, Cilt: 7 - Sayı: 3, 237–241. https://ajindex.com/articles/511534
Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord 2017
[Crossref] 2. Bruni C, Frech T, Manetti M, Rossi FW, Furst DE, De Paulis A, et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: Should the door be closed? Front Immunol 2018
[Crossref] 3. Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017
[Crossref] 4. Volkmann ER CA, Tashkin DP. Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017
[Crossref] 5. Gargani L, Todiere G, Guiducci S, Bruni C, Pingitore A, de Marchi D, et al. Early detection of cardiac involvement in systemic sclerosis: The added value of magnetic resonance imaging. JACC Cardiovasc Imaging 2019
[Crossref] 6. Manetti M, Milia AF, Benelli G, Messerini L, Matucci-Cerinic M, Ibba-Manneschi L. The gastric wall in systemic sclerosis patients: A morphological study. Ital J Anat Embryol 2010
Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016
[Crossref] 8. Bruni C, Cuomo G, Rossi FW, Praino E, Bellando- Randone S. Kidney involvement in Systemic Sclerosis: From pathogenesis to treatment. J Scleroderma Rel Disord 2018
[Crossref] 9. Varjú C, Péntek M, Lóránd V, Nagy G, Minier T, Czirják L. Musculoskeletal involvement in systemic sclerosis: an unexplored aspect of the disease. J Scleroderma Relat Disord 2017
[Crossref] 10. Bruni C, Shirai Y, Kuwana M, Matucci-Cerinic M. Cyclophosphamide: Similarities and differences in the treatment of SSc and SLE. Lupus 2019: 28: 571-4. [Crossref] 11. Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017
[Crossref] 12. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006
[Crossref] 13. Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclero